Table 1.
Clinical features of subjects with primary HIV-1 infection treated with zidovudine, lamivudine, and indinavir
| Subject | Initial CD4 count, cells/μl | CD4 count at time of study, cells/μl | Initial plasma HIV RNA, copies/ml* | Plasma HIV RNA at time of study, copies/ml* |
|---|---|---|---|---|
| 1 | 381 | 1,172 | 3,250,000 | 1,034 |
| 2 | 777 | 1,034 | 22,200 | 267 |
| 3 | 641 | 790 | 96,900 | 343 |
| 4 | 680 | 838 | 12,500 | <50 |
| 5 | 257 | 364 | 38,400 | <50 |
| 6 | 927 | 731 | 6,000,000 | 73 |
| 7 | 378 | 743 | 49,100 | <50 |
| 8 | 397 | 567 | 94,300 | <50 |
| 9 | 601 | 590 | 1,017 | 169 |
| 10 | 559 | 842 | 336,689 | <50 |
Zidovudine (300 mg b.i.d.), lamivudine (150 mg b.i.d.), and indinavir (600 mg q.i.d.).
*
Plasma HIV RNA was measured by using the ultrasensitive reverse transcriptase PCR assay (Roche) with a detection limit of 50 copies/ml.